Remove

NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Application Number		10574903	
	Filing Date		2007-02-28	
	First Named Inventor Trace		cey Jean Brown	
	Art Unit		1644	
	Examiner Name	Share	ron X. Wen	
	Attorney Docket Numb	er	650064.407USPC	

U.S.PATENTS

				0.0	TAILMIS				
Examiner Initial* Cite No Patent Number			Kind Code ¹			tentee or Applicant ument			
	1	5994100	A	1999-11-30	Zhu et al.				
	2	6682904	В1	2004-01-27	Frost				
If you wisi	h to a	dd additional U.S. Pate	nt citatio	n information	please click the	Add button.		Add	
			U.S.P	ATENT APPL	ICATION PUE	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant Rele		Relev	s,Columns,Lines wher ant Passages or Rele es Appear	
If you wis	1 h to a	dd additional U.S. Pubi	ished Ap		on information		d buttor	n. Add	
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	TE
	1	9740174	wo	A1	1997-10-30	LEUKOSITE, INC.			
	2	0881294	EP	A2	1998-12-02	SMITHKLINE BEEF	CHAM		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit Examiner Name

Application Number			10574903		
	Filing Date		2007-02-28		
First Named Inventor Trace		Trace	y Jean Brown		
	Art Unit		1644		
Examiner Name Share		Share	on X. Wen		
	Attorney Docket Number		650064.407USPC		

	4	9800553						\perp	
			wo	A1	1998-01-08	INCYTE PHARMACEUTICALS, INC.			
	5	2002293740	JP	A	2002-10-09	SANSEI SEIYAKU KK		×	
6	6	2004003158	wo	A2	2004-01-08	GENENTECH, INC.			
If you wish	to ac	d additional Foreign Pa				lease click the Add buttor			
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner (Cite No	(book, magazine, journal, senal, symposum, catalog, etc), date, pages(s), volume-issue number(s), publisher, off anolic country hiere published. BULLARD et al., "Hyaluroran Synthase-3 is Upreguished in Melastatic Colon Caronnoma Ceils and Manipulation of Expression Alters Matrix Retention and Cellular Growth," Int. J. Cancer, 107(5):739-746, 2003. HAKANSON et al., "Pri-Intition of hyalurodicise by senan in human cancer," Chemical Abstracts Accession No. 45:15602 S. J. Natl. Cancer Inst., 5:129-132, 1948, (Abstract Only)							
	1								
-	2								
5	3								
4	SIMPSON et al., "Manpulation of Hyalurouss Systhase Expression in Prostate Adenocardinoma Cells Afters Percelular Matin Reterior and Adelesion to bone Marrow Endothelial Cells," J. Biologica Chem., 277 (12):1000-10007. Method ADEC.								
Ę	5 SIMPSON et al., "Inhibition of Prostate Tumor Cell Hyaluronan Synthesis Impairs Subcutaneous Growth and Vascularzation in Immunocompromised Mice," Am. J. Pathol., 161(3) 849-857, September 2002.								

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10574903	
	Filing Date		2007-02-28	
	First Named Inventor	Trace	ey Jean Brown	
	Art Unit		1644	
	Examiner Name	Sharo	on X. Wen	
	Attorney Docket Number		650064.407USPC	

	6	UEXI et al., "Inhibition of hyaluronan synthesis by vesnannone in cultured human myofbroblasts," Biochimica et Biophysica Acta, 1495(2):160-167, 2000.	
	7	ZHANG et al., "Glucocorticoids induce a near-total suppression of hyaluronan synthase mRNA in dermal fibroblasts and in osteroblasts: a molecular mechanism contributing to organ atrophy." Blochemical J., 349(Part 1):91-97, 2000.	
If you wisl	h to a	d additional non-patent literature document citation information please click the Add button Add	

EXAMINER SIGNATURE

Examiner Signature

Date Considered

TEXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include coar of this form with next communication to applicant.

1 See Kind Oodes of USPTO Patent Documents at www.USPTO.GDV or MPEP 801 D.R. *Enter office that issued the document, by the two-letter code (WIPO Social of 13). *For Japanese patent documents, the advisable of the year of the entry of the Emparent must practed the sent number of the patent document. The patent document. The patent document was not sent to the patent document was not precipitately advisable on advisable on advisable on advisable on the patent document was not precipitately advisable on advisable on advisable on advisable on advisable on the patent document was not precipitately advisable on the patent document.